ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

Pfizer invests in China-based CStone

by Lisa M. Jarvis
October 2, 2020 | APPEARED IN VOLUME 98, ISSUE 38

 

Pfizer is taking a stake of roughly 9.9%, worth $200 million, in China-based CStone Pharmaceuticals. The investment is part of a broader collaboration to develop the biotech firm’s PD-L1 antibody sugemalimab in China and bring other cancer therapies to market there. Pfizer will lead marketing of sugemalimab, an immunotherapy in several mid-to-late-stage studies to treat tumors like lung, gastric, and esophageal, which occur at high rates in China. As part of the deal, the partners will pick late-stage cancer therapies from Pfizer’s pipeline or from outside partners to develop in China.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment